RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression
RBM15B-mediated m6A modification of FOXM1 promotes endometrial cancer progression via the AURKA/TPX2 axis.
Asset / Drug
Drug and asset intelligence for RBM15B with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.